Ensysce Biosciences Reaches PF614 Phase 3 Enrollment, Breakthrough Designation; Cash at $4.3M
Ensysce Biosciences initiated PF614-301 Phase 3 enrollment for post-surgical pain and secured FDA Breakthrough Therapy designation plus 505(b)(2) pathway support for PF614-MPAR’s overdose-protection labeling backed by positive clinical data. As of December 31, 2025, the company held $4.3 million cash, supported by $5.1 million in federal grants and expanded patents through 2042.
1. Clinical and Regulatory Milestones
Ensysce initiated its PF614-301 Phase 3 trial for moderate-to-severe post-surgical pain and reported rapid enrollment across multiple U.S. sites, while PF614-MPAR’s MPAR® technology demonstrated overdose protection at a 25 mg dose, earning FDA Breakthrough Therapy designation and support for a streamlined 505(b)(2) pathway.
2. Financial Position
As of December 31, 2025, Ensysce held $4.3 million in cash and cash equivalents, up from $3.5 million a year earlier, and received $5.1 million in federal grant funding for the full year; R&D expenses totaled $10.4 million for 2025.
3. Intellectual Property Expansion
Intellectual property protections were bolstered by a U.S. patent allowance extending MPAR® technology rights through 2042 and a December 2025 Notice of Allowance from the European Patent Office for enzyme-cleavable amphetamine prodrug compositions (PF8026).
4. Pipeline Growth
Beyond PF614, Ensysce advanced its opioid use disorder pipeline with PF9001 as a next-generation methadone alternative under HEAL grant support, and is exploring TAAP™ and MPAR® applications in ADHD and additional indications.